Prevalence of cross-reactive HIV-1-neutralizing activity in HIV-1-infected patients with rapid or slow disease progression

AIDS

Volumn 23, Issue 18, 2009, Pages 2405-2414

  Van Gils, Marit J ^a   Euler, Zelda ^a   Schweighardt, Becky ^b   Wrin, Terri ^b   Schuitemaker, Hanneke ^a  

^a SANQUIN RESEARCH   (Netherlands)

^b MONOGRAM BIOSCIENCES   (United States)

Author keywords

Disease progression; HIV 1; Humoral immunity; Longitudinal; Neutralization

Indexed keywords

VIRUS RNA;

ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS REACTION; DISEASE COURSE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; SEROCONVERSION; VIRUS NEUTRALIZATION;

ANTIBODIES, NEUTRALIZING; CD4 LYMPHOCYTE COUNT; CROSS REACTIONS; DISEASE PROGRESSION; HIV ANTIBODIES; HIV INFECTIONS; HIV-1; HUMANS; MALE; NEUTRALIZATION TESTS; RNA, VIRAL; VIRAL LOAD;

EID: 72949118295     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32833243e7     Document Type: Article

References (34)

1. Burton DR, Desrosiers RC, Doms RW, Koff WC, Kwong PD, Moore JP, et al. HIV vaccine design and the neutralizing antibody problem. Nat Immunol 2004; 5:233-236.
2. Hu SL, Stamatatos L. Prospects of HIV Env modification as an approach to HIV vaccine design. Curr HIV Res 2007; 5:507-513.
3. Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, Parren PWH, et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994; 266:1024-1027.
4. Trkola A, Pomales AB, Yuan H, Korber B, Maddon PJ, Allaway GP, et al. Cross-clade neutralization of primary isolates of human immunodeficiency virus type 1 by human monoclonal antibodies and tetrameric CD4-IgG. J Virol 1995; 69:6609-6617.
5. Muster T, Steindl F, Purtscher M, Trkola A, Klima A, Himmler G, et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 1993; 67:6642-6647.
6. Stiegler G, Kunert R, Purtscher M, Wolbank S, Voglauer R, Steindl F, et al. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 2001; 17:1757-1765.
7. Dhillon AK, Donners H, Pantophlet R, Johnson WE, Decker JM, Shaw GM,etal. Dissectingthe neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J Virol 2007; 81:6548-6562.
8. Binley JM, Lybarger EA, Crooks ET, Seaman MS, Gray E, Davis KL, et al. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J Virol 2008; 82:11651-11668.
9. Li Y, Svehla K, Louder MK, Wycuff D, Phogat S, Tang M, et al. Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J Virol 2009; 83:1045-1059.
10. Sather DN, Armann J, Ching LK, Mavrantoni A, Sellhorn G, Caldwell Z, et al. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol 2009; 83:757-769.
11. Doria-Rose NA, Klein RM, Manion MM, O'Dell S, Phogat A, Chakrabarti B, et al. Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. J Virol 2009; 83:188-199.
12. Pereyra F, Addo MM, Kaufmann DE, Liu Y, Miura T, Rathod A, et al. Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J Infect Dis 2008; 197:563-571.
13. Li Y, Migueles SA, Welcher B, Svehla K, Phogat A, Louder MK, et al. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med 2007; 13:1032-1034.
14. Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 2003; 100:4144-4149.
15. Brown BK, Wieczorek L, Sanders-Buell E, Rosa BA, Robb ML, Birx DL, et al. Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models. Virology 2008; 375:529-538.
16. Cheng-Mayer C, Homsy J, Evans LA, Levy JA. Identification of human immunodeficiency virus subtypes with distinct patterns of sensitivity to serum neutralization. Proc Natl Acad Sci U S A 1988; 85:2815-2819.
17. Kostrikis LG, Cao Y, Ngai H, Moore JP, Ho DD. Quantitative analysis of serum neutralization of human immunodeficiency virus type 1 from subtypes A, B, C, D, E, F, and I: lack of direct correlation between neutralization serotypes and genetic subtypes and evidence for prevalent serum-dependent infectivity enhancement. J Virol 1996; 70:445-458.
18. Moore JP, Cao Y, Leu J, Qin L, Korber B, Ho DD. Inter-and intraclade neutralization of human immunodeficiency virus type 1: genetic clades do not correspond to neutralization serotypes but partially correspond to gp120 antigenic sero-types. J Virol 1996; 70:427-444. (Pubitemid 126508812)
19. Griensven van GJP, VroomedeEMM, GoudsmitJ,Coutinho RA. Changes in sexual behavior and the fall in incidence of HIV infection among homosexual men. BMJ 1989; 298:218-221.
20. Mascola JR, D'Souza P, Gilbert P, Hahn BH, Haigwood NL, Morris L, et al. Recommendations for the design and use of standard virus panels to assess neutralizing antibody responses elicited by candidate human immunodeficiency virus type 1 vaccines. J Virol 2005; 79:10103-10107.
21. SchweighardtB,LiuY,HuangW,ChappeyC,LieYS, Petropoulos CJ, et al. Development of an HIV-1 reference panel of subtype B envelope clones isolated from the plasma of recently infected individuals. J Acquir Immune Defic Syndr 2007; 46:1-11.
22. Simek MD, Rida W, Priddy FH, Pung P, Carrow E, Laufer DS, et al. HIV-1 elite neutralizers: individuals with broad and potent neutralizing activity identified using a high throughput neutralization assay together with an analytical selection algorithm. J Virol 2009; 83:7337-7348.
23. Petropoulos CJ, Parkin NT, Limoli KL, Lie YS, Wrin T, Huang W, et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 2000; 44:920-928.
24. Brown BK, Darden JM, Tovanabutra S, Oblander T, Frost J, Sanders-Buell E, et al. Biologic and genetic characterization of a panel of 60 human immunodeficiency virus type 1 isolates, representing clades A, B, C, D, CRF01-AE, and CRF02-AG, for the development and assessment of candidate vaccines. J Virol 2005; 79:6089-6101.
25. Tersmette M, Winkel IN, Groenink M, Gruters RA, Spence P, Saman E, et al. Detection and subtyping of HIV-1 isolates with a panel of characterized monoclonal antibodies to HIV-p24 gag. Virology 1989; 171:149-155.
26. Fenyo EM, Heath A, Dispinseri S, Holmes H, Lusso P, Zolla-Pazner S, et al. International network for comparison of HIV neutralization assays: the NeutNet report. PLoS ONE 2009; 4:e4505.
27. Recher M, Lang KS, Hunziker L, Freigang S, Eschli B, Harris NL, et al. Deliberate removal of T cell help improves virus-neutralizing antibody production. Nat Immunol 2004; 5: 934-942.
28. Lang KS, Hegazy AN, Lang PA, EschliB, LohningM,Hengartner H, et al. 'Negative vaccination' by specific CD4 T cell tolerisa-tion enhances virus-specific protective antibody responses. PLoS ONE 2007; 2:e1162.
29. Scheid JF, Mouquet H, Feldhahn N, Seaman MS, Velinzon K, Pietzsch J, et al. Broad diversity of neutralizing antibodies isolated from memory B cells in HIV-infected individuals. Nature 2009; 458:636-640.
30. Trkola A, Kuster H, Rusert P, von Wyl V, Leemann C, Weber R, et al. In vivo efficacy of human immunodeficiency virus neutralizing antibodies: estimates for protective titers. J Virol 2008, 82:1591-1599.
31. Nishimura Y, Igarashi T, Haigwood N, Sadjadpour R, Plishka RJ, Buckler-White A, et al. Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies. J Virol 2002; 76:2123-2130.
32. Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, Forthal DN, et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog 2009; 5:e1000433.
33. Poignard P, Sabbe R, Picchio GR, Wang M, Gulizia RJ, Katinger H, et al. Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. Immunity 1999; 10:431-438.
34. Barouch DH. Challenges in the development of an HIV-1 vaccine. Nature 2008; 455:613-619.